Genmab to acquire Merus for $8 billion
Proposed acquisition adds petosemtamab, a late-stage asset with two Breakthrough Therapy Designations, to Genmab’s portfolio
Proposed acquisition adds petosemtamab, a late-stage asset with two Breakthrough Therapy Designations, to Genmab’s portfolio
The product will be manufactured at Lupin’s Chhatrapati Sambhajinagar facility in India
India currently hosts more than 10,075 biotech startups
BPDCN is a challenging blood cancer with characteristics of both leukemia and lymphoma
Eliquis (apixaban) available at more than 40 per cent discount; Sotyktu to be offered at more than 80 per cent discount to current list price
Brenntag will showcase forward-looking formulations designed to respond to Indonesia’s evolving beauty and self-care needs
FDA authorization was based on two years of clinical study data demonstrating that Essilor Stellest lenses significantly slowed myopia progression compared to single-vision control lenses
Harmonisation of listing structure requires a direct listing of AstraZeneca shares on the NYSE in place of existing US ADRs
Subscribe To Our Newsletter & Stay Updated